Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial за авторством Sweet, K, Dasgupta, B, De Vries, D, Gourley, I, Hsu, B, Loza, M, Taylor, P